Does Troponin I evaluation identify trastuzumab-treated patients at risk for cardiotoxicity and lack of recovery from cardiac dysfunction?
Troponin I positivity identifies trastuzumab-treated patients at high risk for irreversible cardiotoxicity, highlighting its prognostic value in cardio-oncology.
TNI+ identifies trastuzumab-treated patients who are at risk for cardiotoxicity and are unlikely to recover from cardiac dysfunction despite HF therapy.
Cardinale et al. (2010) studied this question.